Zymeworks confirms $773m buyout offer from All Blue Capital

Zymeworks, a Vancouver-based provider of multifunctional biotherapeutics, has confirmed its receipt of an unsolicited, non-binding acquisition proposal from an affiliate of All Blue Capital.